CSafe, an active and passive temperature-controlled shipping solutions provider for the biopharmaceutical industry, launched a new line of cryogenic multi-use dewars for the cell and gene therapy market. The technology, part of CSafe’s CGT Cryo Series, maintains temperatures colder than -150°C.   The reusable dewars and high-impact-resistant shipping cases are engineered to securely transport critical cell and gene therapies, including pre-frozen biologic materials, regenerative medicine...